Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

MLAB vs SVRE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MLAB Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 10–0 Matrix Metrics)

MLAB Overall Winner 6-Pillar Tally: MLAB 5 – 0 SVRE (1 Tie) Matrix Metrics: MLAB 10 – 0 SVRE

As of Nov 17, 2026, Mesa Laboratories Inc (MLAB) is the stronger overall head-to-head candidate over SaverOne 2014 Ltd. (SVRE) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MLAB carries a Unified Composite Score of 41.6/100 (SELL) at $135.27 (24.9x Forward P/E, 10.4% operating margin), whereas SVRE carries 39.3/100 (SELL) at $0.43 (N/M Forward P/E, 0.0% operating margin).

  • Defensive Composite Rating Caution: Although MLAB compares more favorably head-to-head, both MLAB (41.6/100 SELL) and SVRE (39.3/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: MLAB trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 54.3); meanwhile SVRE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MLAB vs SVRE
MLAB NASDAQ Head-to-Head Winner
Mesa Laboratories Inc
Industrial Instruments For Measurement, Display, And Control
$135.27
+0.88% 1D
Market Cap $781.3M
TTM Revenue $251M
Forward P/E 24.9x
Beta / 30D Vol 1.14β · 54% Vol
Unified Composite Score
41.6 / 100 SELL
Tech 20.0 Fund 32.0 Flow 50.0 Mom 44.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (3.1% over 20 days), RSI 54
RSI-14: 54.3 · SMA20: $129.84 · SMA50: $129.16
SVRE NASDAQ
SaverOne 2014 Ltd. American Depositary Shares
Services-Computer Programming Services
$0.43
-1.46% 1D
Market Cap $1.1M
TTM Revenue $2.0M
Forward P/E N/M
Beta / 30D Vol 0.49β · 190% Vol
Unified Composite Score
39.3 / 100 SELL
Tech 25.0 Fund 46.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -36.4%), weak momentum, RSI 28
RSI-14: 28.4 · SMA20: $0.89 · SMA50: $1.47

6-Pillar Scorecard Institutional Category Breakdown (MLAB 5 – 0 SVRE)

Columns: Metric · MLAB · SVRE
1. Valuation Multiples MLAB
Forward P/E 24.9x N/M
Trailing P/E 119.8x N/M
PEG Ratio N/M N/M
EV / Revenue 3.1x 0.6x
2. Growth & Scale MLAB
Revenue Growth (YoY) +2.6% -63.0%
Earnings Growth (YoY) +67.0% +0.0%
TTM Revenue (USD) $251M $2.0M
Market Cap $781.3M $1.1M
3. Profitability & Quality MLAB
Gross Margin 64.8% -41.1%
Operating Margin 10.4% 0.0%
Net Profit Margin 2.6% 0.0%
Return on Equity (ROE) 3.6% -151.1%
4. Balance Sheet & Cash Flow MLAB
Cash Generation (TTM) $49M EBITDA -$34M EBITDA
Cash Flow Margin 19.4% EBITDA Mgn N/A
Net Cash / Leverage $34.66 Book/Sh · 3.6% ROE $0.00 Book/Sh · -151.1% ROE
Dividend Yield 0.47% None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat MLAB
OpEx & R&D Intensity 54.4% of Rev ($137M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Scientific & Technical Instruments Operator Scientific & Technical Instruments Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MLAB (10) vs SVRE (0)
Institutional Metric MLAB SVRE Criterion Row Edge
Market Capitalization
Scale
$781.3M $1.1M Larger Scale MLAB
Trailing P/E Ratio
Valuation
119.8x N/M Lower Multiple MLAB
Forward P/E Ratio
Valuation
24.9x N/M Lower Multiple MLAB
Revenue Growth (YoY)
Growth
+2.6% -63.0% Higher Growth MLAB
Operating Margin (TTM)
Profitability
10.4% 0.0% Higher Margin MLAB
Net Profit Margin
Profitability
2.6% 0.0% Higher Margin MLAB
Return on Equity (ROE)
Capital Efficiency
3.6% -151.1% Higher ROE MLAB
52-Week Range Position
Momentum
88% ($70–$144) 0% ($0–$6) Stronger Trend MLAB
Beta / 30D Volatility
Risk Regime
1.14β · 54% Vol 0.49β · 190% Vol Lower Realized Risk MLAB
Unified Institutional Score
Composite Signal
41.6 / 100 (SELL) 39.3 / 100 (SELL) Higher Composite MLAB
Trailing 12M Revenue (USD)
Operating Scale
$251M $2.0M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
64.8% -41.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.1x EV/Rev N/M PEG · 0.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$49M EBITDA ($34.66 Book/Sh · 3.6% ROE) -$34M EBITDA ($0.00 Book/Sh · -151.1% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MLAB +85.95 pp
MLAB: +9.7% · SVRE: -76.25%
3M Horizon MLAB +98.07 pp
MLAB: +12.99% · SVRE: -85.08%
6M Horizon MLAB +125.05 pp
MLAB: +35.5% · SVRE: -89.55%
1Y Horizon MLAB +139.6 pp
MLAB: +82.94% · SVRE: -56.66%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MLAB vs SVRE. Trailing 12-month operating profitability (MLAB 10.4% vs SVRE 0.0%) and valuation multiples (MLAB 24.9x vs SVRE N/M Forward P/E) are benchmarked directly in Pillar 4 below.

MLAB ADR TTM Benchmark FX-Normalized USD
TTM Revenue$251M
Gross Margin64.8%
Op. Margin10.4%
ROE / Fwd P/E3.6% · 24.9x
SVRE ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.0M
Gross Margin-41.1%
Op. Margin0.0%
ROE / Fwd P/E-151.1% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MLAB UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MLAB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SVRE UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SVRE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MLAB Moat Profile Cyclical / Execution-Driven Positioning
Scientific & Technical Instruments Operator
Competes within the Scientific & Technical Instruments value chain with $781.3M market capitalization and 10.4% operating margin.
OpEx & R&D Reinvestment 54.4% of Rev ($137M)
90D Engineering Disclosures 0 Published
SVRE Moat Profile Cyclical / Execution-Driven Positioning
Scientific & Technical Instruments Operator
Competes within the Scientific & Technical Instruments value chain with $1.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MLAB vs SVRE Key Questions & Quantitative Answers

As of Nov 17, 2026, Mesa Laboratories Inc (MLAB) is the stronger overall head-to-head candidate over SaverOne 2014 Ltd. (SVRE) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MLAB carries a Unified Composite Score of 41.6/100 (SELL) at $135.27 (24.9x Forward P/E, 10.4% operating margin), whereas SVRE carries 39.3/100 (SELL) at $0.43 (N/M Forward P/E, 0.0% operating margin). Defensive Composite Rating Caution: Although MLAB compares more favorably head-to-head, both MLAB (41.6/100 SELL) and SVRE (39.3/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: MLAB trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 54.3); meanwhile SVRE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MLAB leads the Growth & Scale pillar: MLAB posts +2.6% YoY revenue growth and +67.0% YoY earnings growth on $251M TTM revenue (64.8% gross margin, 10.4% operating margin), compared with SVRE at -63.0% YoY revenue growth and +0.0% YoY earnings growth on $2.0M TTM revenue (-41.1% gross margin, 0.0% operating margin). On trailing 12-month operating scale, MLAB generates $251M in USD-normalized revenue versus $2.0M for SVRE. In operating R&D and SG&A reinvestment, MLAB deploys 54.4% of Rev ($137M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SVRE.

MLAB screens cheaper on headline valuation multiples. MLAB trades at 24.9x Forward P/E, 119.8x Trailing P/E, N/M PEG, and 3.1x EV/Revenue (19.4% EBITDA margin), whereas SVRE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.6x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MLAB (3.6% ROE) versus SVRE (-151.1% ROE) capital efficiency.

In options market volatility and institutional positioning, MLAB carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.14β · 54% Vol realized risk). By comparison, SVRE carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.49β · 190% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.